AI-driven drug discovery

ChatGPT may be one of the quickest adopted tech platforms in recent memory, but the potential of it and other large language models ability transform the world has also been met with occasional provider outages, hallucinations, and memory problems. “There’s a lot of resentment towards the hype,” notes Christopher M. McSpiritt, head of life sciences…

The potential of Artificial Intelligence (AI) to accelerate medical discovery is immense, particularly within the dynamic and mutable area of biology. Unlike the more predictable fields of chemistry and physics, biology presents unique challenges due to its complexity and constant adaptation, areas where AI can play a transformative role but has been limited to date…

Imagine sifting through medical and genetic histories to understand why some patients respond to treatments while others don’t. This is the reality for companies like Merck & Co. A recent pact with Culmination Bio is giving Merck access to more than 40 years of data, including millions of biospecimens to fuel this aim. “We want…

Idiopathic Pulmonary Fibrosis (IPF), a devastating lung disease affecting millions with increasing incidence, may have a new treatment hope thanks to a novel inhibitor of TNIK, a kinase newly implicated in fibrosis, identified using generative AI drug discovery platforms in just 18 months. Researchers at Insilico Medicine, along with international collaborators, harnessed the power of…

Insilico Medicine, an AI-based biotech startup, announced details of their first AI-designed drug candidate to enter human clinical trials. INS018_055 is an experimental treatment for idiopathic pulmonary fibrosis, a rare lung disease. Through their Insilico AI-driven drug discovery platform, they discovered and designed INS018_055 in just 30 months, significantly faster than the industry average. Phase…